Literature DB >> 16275849

Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study.

K Buerger1, M Ewers, N Andreasen, R Zinkowski, K Ishiguro, E Vanmechelen, S J Teipel, C Graz, K Blennow, H Hampel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16275849     DOI： 10.1212/01.wnl.0000183284.92920.f2

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  22 in total

1.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Authors:  Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

3.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

4.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Authors:  Barbara J Snider; Anne M Fagan; Catherine Roe; Aarti R Shah; Elizabeth A Grant; Chengjie Xiong; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2009-05

Review 5.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 6.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

7.  Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michael L Alosco; Beth A Jerskey; Lawrence H Sweet; Brian R Ott; Geoffrey Tremont
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

Review 8.  Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.

Authors:  Dezhi Liao; Eric C Miller; Peter J Teravskis
Journal:  Eur J Neurosci       Date:  2014-04       Impact factor: 3.386

9.  Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-14

Review 10.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.